Celldex Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2017
Filed with the SEC on May 9, 2017 and accepted by EDGAR at May 9, 2017, 16:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2017-01-01 to 2017-03-31 | $1.5m | us-gaap:Revenues |
| Research and development | 3 months2017-01-01 to 2017-03-31 | $25.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-01-01 to 2017-03-31 | −$35.1m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2017-01-01 to 2017-03-31 | −$34.3m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2017-01-01 to 2017-03-31 | −$0.28 | us-gaap:EarningsPerShareBasicAndDiluted |
| Capital expenditure | 3 months2017-01-01 to 2017-03-31 | $374.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-03-31 | $42.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-03-31 | $173.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-03-31 | $360.0m | us-gaap:Assets |
| Current liabilities | At period end2017-03-31 | $27.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-03-31 | $112.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-03-31 | $247.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-17-031139. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.